This is a potentially huge problem, because it could mean that Novartis may face exclusion - a term that means the drugmaker could be excluded from having contracts with federal healthcare programs, such as Medicare and Medicaid.
In such a reorganization, a state could propose to terminate some, all or none of its government employee union contracts and establish new compensation rates, work rules, etc.